| The role of somatostatin analogues in the treatment of neuroendocrine tumours. | |
| | |
MedLine Citation:
|
PMID: 18037561 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Neuroendocrine tumours belong to a heterogeneous family of neoplasms, originating in endocrine glands (such as the pituitary, parathyroid or the neuroendocrine adrenal glands), in endocrine islets (within the thyroid or pancreas) as well as in endocrine cells dispersed between exocrine cells throughout the digestive or respiratory tracts. The clinical behaviour of neuroendocrine tumours is variable; they may be functioning or not functioning, ranging from well-differentiated slow growing neuroendocrine tumours to poorly differentiated neuroendocrine tumours, which are highly aggressive malignant tumours. The development of somatostatin analogues as important diagnostic and treatment tools have revolutionised the clinical management of patients with neuroendocrine tumours. However, although symptomatic relief and stabilisation of tumour growth for various periods of time are observed in many patients treated with somatostatin analogues, tumour regression is rare. Development of new somatostatin analogues and new drug combination therapies should further improve the clinical management of these patients. |
| | |
Authors:
|
Simona Grozinsky-Glasberg; Ashley B Grossman; Márta Korbonits |
Publication Detail:
|
Type: Journal Article; Review Date: 2007-10-13 |
Journal Detail:
|
Title: Molecular and cellular endocrinology Volume: 286 ISSN: 1872-8057 ISO Abbreviation: Mol. Cell. Endocrinol. Publication Date: 2008 May |
Date Detail:
|
Created Date: 2008-05-20 Completed Date: 2009-07-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7500844 Medline TA: Mol Cell Endocrinol Country: Ireland |
Other Details:
|
Languages: eng Pagination: 238-50 Citation Subset: IM |
Affiliation:
|
Department of Endocrinology, William Harvey Research Institute, Barts and the London, Queen Mary School of Medicine, University of London, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Gland Neoplasms
/
drug therapy Antineoplastic Agents, Hormonal / therapeutic use* Carcinoma, Bronchogenic / drug therapy Female Humans Neuroendocrine Tumors / drug therapy* Ovarian Neoplasms / drug therapy Pancreatic Neoplasms / drug therapy Paraganglioma / drug therapy Pheochromocytoma / drug therapy Pituitary Neoplasms / drug therapy Somatostatin / analogs & derivatives*, therapeutic use* Thyroid Neoplasms / drug therapy |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Hormonal; 51110-01-1/Somatostatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of contrast-enhanced color Doppler imaging (CDI), computed tomography (CT), and magnetic ...
Next Document: LIBS-an efficient approach for the determination of Cr in industrial wastewater.